Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xilio Therapeutics, Inc.XLO · Entity 7122 | CHIEF FINANCIAL OFFICER | February 22, 2022 | February 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xilio Therapeutics, Inc.
Report date February 22, 2022 · Filed February 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.66 · Expires 2032-02-21 | Direct | 49,500 |
Reported balance
After 2022-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-22 · Grant · Acquired 49,500 · Balance 49,500 F1: The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2022 Filed Feb 24, 2022 22:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 49,500 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001415889-22-001793 · form4-02242022_050215.xml · derivative · entry 1 Giovine Salvatore · CIK 0001887790 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 Underlying: Common Stock · 49,500 shares Expires 2032-02-21 F1 · derivative.exercise_date: The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 21:16 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 28,755 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-21-129565 · tm2130646-20_4seq1.xml · derivative · entry 1 Giovine Salvatore · CIK 0001887790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,755 Underlying: Common Stock · 28,755 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option award was granted on October 21, 2021 and shall begin to vest on November 1, 2021 and continue to vest in equal monthly installments thereafter until October 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.